Dendreon cuts deep into work force to conserve cash

In an attempt to break even in the cash-intensive biotech game following a rough start with its prostate cancer drug, Dendreon is handing pink slips to a quarter of its employees and saying goodbye to COO Hans Bishop.

The job cuts announced yesterday were expected after the Seattle-based biotech ($DNDN) disappointed with lower-than-expected sales of Provenge, its innovative immunotherapy against prostate tumors. Roughly 80% of the jobs being slashed come from the manufacturing organization quickly amassed in recent years to prepare for the drug's launch, according to a Seattle Times article. About 100 workers in Seattle who hold back-office and finance jobs also are getting walking papers, the paper reports.

"When we realized we would not be on a run rate of $175 million to $200 million in the fourth quarter, we had to reduce the head count in our plants to a more gradual ramp," Dendreon CEO Mitch Gold told the Times. The company provided scant details about Bishop's departure.

Dendreon reported $22 million in Provenge sales last month, and executives said its revenue outlook, work-force reduction savings and its $600 million in available capital at the end of August were sufficient to climb out of the red and reach a break-even point. But Wall Street seemed unmoved by the restructuring, and the firm's stock was trading this morning at around $11 per share, down about 70% since the now infamous sales numbers were released in early August.

- here's the company's release
- see the Seattle Times' report

Suggested Articles

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.

In our EuroBiotech roundup this week, Nordic Nanovector delays phase 2b readout, PPF buys big Autolus stake and Poxel shares phase 3 diabetes data.